<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2b6cc6a4-9e7b-4066-9936-e23a753b7547"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      These highlights do not include all the information needed to use MOZOBIL safely and effectively.  See full prescribing information for MOZOBIL.<br/>
      <br/>
      
      MOZOBIL (plerixafor injection), Solution for Subcutaneous use<br/>
      Initial U.S. Approval: 2008
   </title>
   <effectiveTime value="20100812"/>
   <setId root="a56b1b78-0ae2-41b4-9c76-98ad9d439199"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="025322157" root="1.3.6.1.4.1.519.1"/>
            <name>Genzyme Corporation</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="237710418" root="1.3.6.1.4.1.519.1"/>
                        <name>Patheon</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="229522842" root="1.3.6.1.4.1.519.1"/>
                        <name>Genzyme Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="098066215" root="1.3.6.1.4.1.519.1"/>
                        <name>Genzyme Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="b366fdb1-42f3-4f0d-b6af-b528db2de4cb"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL LISTING DATA ELEMENTS SECTION"/>
               <effectiveTime value="20090731"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="58468-0140" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Mozobil</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>PLERIXAFOR</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="24"/>
                              <denominator unit="mL" value="1.2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="S915P5499N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PLERIXAFOR</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="S915P5499N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PLERIXAFOR</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="5.9"/>
                              <denominator unit="mL" value="1.2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1.2"/>
                              <denominator value="1.0"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-USE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1">
                                       <translation code="C48551" codeSystem="2.16.840.1.113883.3.26.1.1" value="1" displayName="VIAL"/>
                                    </numerator>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="58468-0140-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022311" root="2.16.840.1.113883.3.150"/>
                           <code displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1" code="C73594"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20081215"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="c1a2ef8e-2e9c-45e5-b584-d57436d99d34">
               <id root="40507238-58d0-4ad6-9c5a-bb8b7f9c5d9c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph> Mozobil<sup>®</sup> (plerixafor injection) is indicated in combination
                     with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic
                     stem cells to the peripheral blood for collection and subsequent autologous
                     transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple
                     myeloma (MM). </paragraph>
               </text>
               <effectiveTime value="20090807"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph> Mozobil, a hematopoietic stem cell mobilizer, is indicated in
                           combination with granulocyte-colony stimulating factor (G-CSF) to
                           mobilize hematopoietic stem cells to the peripheral blood for collection
                           and subsequent autologous transplantation in patients with non-Hodgkin’s
                           lymphoma and multiple myeloma. (<linkHtml href="#c1a2ef8e-2e9c-45e5-b584-d57436d99d34">1</linkHtml>)
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="e7594295-ab3c-4c11-a075-b95f0c37b75d">
               <id root="a6477575-c576-4736-86d7-206ec4adc9d5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20090807"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph> •    Initiate Mozobil treatment after the patient has received
                           G-CSF once daily for 4 days. (<linkHtml href="#c7052a30-f0a9-407a-87f7-5c4942f151cb">2.1</linkHtml>) </paragraph>
                        <paragraph> •    Repeat Mozobil dose up to 4 consecutive days. (<linkHtml href="#c7052a30-f0a9-407a-87f7-5c4942f151cb">2.1</linkHtml>) </paragraph>
                        <paragraph> •    Select dose based on 0.24 mg/kg actual body weight.
                              (<linkHtml href="#c7052a30-f0a9-407a-87f7-5c4942f151cb">2.1</linkHtml>) </paragraph>
                        <paragraph> •    Administer by subcutaneous injection approximately 11 hours
                           prior to initiation of apheresis. (<linkHtml href="#c7052a30-f0a9-407a-87f7-5c4942f151cb">2.1</linkHtml>) </paragraph>
                        <paragraph> •    Renal impairment:  If creatinine clearance is ≤ 50 mL/min,
                           decrease dose by one-third to 0.16 mg/kg. (<linkHtml href="#b7351d1e-52b7-49ba-bc0d-a6aca4498a91">2.3</linkHtml>)
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="c7052a30-f0a9-407a-87f7-5c4942f151cb">
                     <id root="049d71a7-7847-44e5-9839-3e882d917821"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage and Administration</title>
                     <text>
                        <paragraph>Vials should be inspected visually for particulate matter and
                           discoloration prior to administration and should not be used if there is
                           particulate matter or if the solution is discolored.</paragraph>
                        <paragraph> Begin treatment with Mozobil after the patient has received
                           G-CSF once daily for four days. <content styleCode="italics">
                              <content styleCode="emphasis">[see</content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <linkHtml href="#df7d23fe-56c8-493a-b81e-46b20e49d0c7"> Dosage and
                                    Administration (2.2)</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">] </content>
                           </content> Administer Mozobil approximately 11 hours prior to initiation
                           of each apheresis for up to 4 consecutive days. </paragraph>
                        <paragraph>The recommended dose of Mozobil is 0.24 mg/kg body weight by
                           subcutaneous (SC) injection. Use the patient’s actual body weight to
                           calculate the volume of Mozobil to be administered. Each vial delivers
                           1.2 mL of 20 mg/mL solution, and the volume to be administered to
                           patients should be calculated from the following equation:</paragraph>
                        <paragraph>    0.012 X patient’s actual body weight (in kg) = volume to be
                           administered (in mL)</paragraph>
                        <paragraph>In clinical studies, Mozobil dose has been calculated based on
                           actual body weight in patients up to 175% of ideal body weight. Mozobil
                           dose and treatment of patients weighing more than 175% of ideal body
                           weight have not been investigated. </paragraph>
                        <paragraph> Based on increasing exposure with increasing body weight, the
                           plerixafor dose should not exceed 40 mg/day. <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">[see </content>
                                 </content>
                                 <linkHtml href="#f20a0ec7-0d1d-4f36-b7de-b7cbb354d273">Clinical
                                    Pharmacology (12.3)</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">]</content>
                           </content>  </paragraph>
                     </text>
                     <effectiveTime value="20090807"/>
                  </section>
               </component>
               <component>
                  <section ID="df7d23fe-56c8-493a-b81e-46b20e49d0c7">
                     <id root="d2cc038f-08e2-4eef-a82b-48a6550d72af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Concomitant Medications</title>
                     <text>
                        <paragraph> Administer daily morning doses of G-CSF 10 micrograms/kg for 4
                           days prior to the first evening dose of Mozobil and on each day prior to
                           apheresis. <content styleCode="italics">
                              <content styleCode="emphasis">[see </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <linkHtml href="#e783297a-d785-4ab5-85a1-1f3abcb5fce5"> Clinical
                                    Studies (14)</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">]</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
               <component>
                  <section ID="b7351d1e-52b7-49ba-bc0d-a6aca4498a91">
                     <id root="87b911d3-7e1f-4a43-b70e-15fd56114960"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosing in Renal Impairment</title>
                     <text>
                        <paragraph> In patients with moderate and severe renal impairment (estimated
                           creatinine clearance (CL<sub>CR</sub>) ≤ 50 mL/min), reduce the dose of
                           Mozobil by one-third to 0.16 mg/kg as shown in <linkHtml href="#b019781f-fa59-4c6d-aafc-719dd3fb73bd"> Table 1</linkHtml>. If
                              CL<sub>CR</sub> is ≤ 50 mL/min the dose should not exceed 27 mg/day,
                           as the mg/kg-based dosage results in increased plerixafor exposure with
                           increasing body weight. <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">[see </content>
                                 </content>
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">
                                       <linkHtml href="#f20a0ec7-0d1d-4f36-b7de-b7cbb354d273">
                                          Clinical Pharmacology (12.3)</linkHtml>
                                    </content>
                                 </content>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">]</content>
                           </content>  Similar systemic exposure is predicted if the dose is reduced
                           by one-third in patients with moderate and severe renal impairment
                           compared with subjects with normal renal function. <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">[see </content>
                                 </content>
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">
                                       <linkHtml href="#f20a0ec7-0d1d-4f36-b7de-b7cbb354d273">
                                          Clinical Pharmacology (12.3)</linkHtml>
                                    </content>
                                 </content>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">]</content>
                           </content>  </paragraph>
                        <table ID="b019781f-fa59-4c6d-aafc-719dd3fb73bd">
                           <caption>Table 1: Recommended Dosage of Plerixafor in Patients with Renal
                              Impairment</caption>
                           <colgroup>
                              <col align="center"/>
                              <col width="60%" align="center"/>
                           </colgroup>
                           <thead styleCode="Lrule Rrule Toprule Botrule">
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                                         Estimated Creatinine
                                    Clearance     <br/>(mL/min) </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center">Dose</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">&gt; 50</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                        0.24 mg/kg once daily (not to
                                    exceed 40 mg/day)      </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">≤ 50</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">
                                        0.16 mg/kg once daily (not to
                                    exceed 27 mg/day)      </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> The following (Cockroft-Gault) formula may be used to estimate
                              CL<sub>CR</sub>:  </paragraph>
                        <paragraph>     Males:<br/>    Creatinine clearance (mL/min) = <content styleCode="underline">
                              <content styleCode="emphasis">
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">weight (kg) X (140 – age in
                                    years)</content>
                                 </content>
                                 <br/>
                              </content>
                           </content>                                                            72
                           X serum creatinine (mg/dL) </paragraph>
                        <paragraph>     Females:<br/>    Creatinine clearance (mL/min) = 0.85 X
                           value calculated for males </paragraph>
                        <paragraph>There is insufficient information to make dosage recommendations
                           in patients on hemodialysis.</paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="cd04d227-02eb-4144-a9a1-776b2d6e085a">
               <id root="7f2a7c2c-cf77-4199-ad5f-6e9d8821513d"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Single-use vial containing 1.2 mL of a 20 mg/mL solution.</paragraph>
               </text>
               <effectiveTime value="20090528"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph> •   Single-use vial containing 1.2 mL of a 20 mg/mL solution.
                              (<linkHtml href="#cd04d227-02eb-4144-a9a1-776b2d6e085a">3</linkHtml>)
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="af262957-224c-4d4e-94d4-6e8f486d6a2d">
               <id root="90b4b8c9-6f84-4573-9e6b-dd33f1638a17"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20090528"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph> •   None. (<linkHtml href="#af262957-224c-4d4e-94d4-6e8f486d6a2d">4</linkHtml>)
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="e914ac11-1e1f-48a2-a22c-ce8a6f97467c">
               <id root="6f89b2df-137b-40c6-94e5-94a1b1050c81"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20090810"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item> Tumor Cell Mobilization in Leukemia Patients: Mozobil may mobilize
                              leukemic cells and should not be used in leukemia patients. (<linkHtml href="#a65b9721-3f7e-4e02-ba13-c6974230e27f">5.1</linkHtml>) </item>
                           <item> Hematologic Effects: Increased circulating leukocytes and
                              decreased platelet counts have been observed.  Monitor blood cell
                              counts and platelet counts during Mozobil use. (<linkHtml href="#adcfe034-9bc4-4959-b7b8-b44d0a0f6faf">5.2</linkHtml>) </item>
                           <item> Potential for Tumor Cell Mobilization:  Tumor cells may be
                              released from marrow during HSC mobilization with Mozobil and G-CSF. 
                              Effect of reinfusion of tumor cells is unknown. (<linkHtml href="#f65864d6-8beb-414c-bce9-210a81087a6b">5.3</linkHtml>) </item>
                           <item> Potential for Splenic Rupture: Evaluate patients who report left
                              upper abdominal and/or scapular or shoulder pain. (<linkHtml href="#f311f15b-c5d5-49d2-a3b0-de05bafc500d">5.4</linkHtml>) </item>
                           <item> Pregnancy: May cause fetal harm.  Advise women not to become
                              pregnant when taking Mozobil.  (<linkHtml href="#a79cecb1-cc43-4f35-ab7d-5f45f78cc7ef">5.5</linkHtml>,
                                 <linkHtml href="#d7b6e62c-85a0-4317-ba10-602e810bcf7c">8.1</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="a65b9721-3f7e-4e02-ba13-c6974230e27f">
                     <id root="a9d77c26-5bdc-4f40-933c-cfaeec005d26"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Tumor Cell Mobilization in Leukemia Patients</title>
                     <text>
                        <paragraph>For the purpose of HSC mobilization, Mozobil may cause
                           mobilization of leukemic cells and subsequent contamination of the
                           apheresis product. Therefore, Mozobil is not intended for HSC
                           mobilization and harvest in patients with leukemia.</paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
               <component>
                  <section ID="adcfe034-9bc4-4959-b7b8-b44d0a0f6faf">
                     <id root="9e6626a1-d363-47df-a2cf-b466e62148cf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hematologic Effects</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis"> Leukocytosis </content>
                                 </content>
                              </content>
                           </content>
                           <br/>Administration of Mozobil in conjunction with G-CSF increases
                           circulating leukocytes as well as HSC populations. Monitor white blood
                           cell counts during Mozobil use. Exercise clinical judgment when
                           administering Mozobil to patients with peripheral blood neutrophil counts
                           above 50,000/mcL. </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis"> Thrombocytopenia</content>
                                 </content>
                                 <br/>
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis"/>
                                 </content>
                              </content>
                           </content>Thrombocytopenia has been observed in patients receiving
                           Mozobil. Monitor platelet counts in all patients who receive Mozobil and
                           then undergo apheresis. </paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
               <component>
                  <section ID="f65864d6-8beb-414c-bce9-210a81087a6b">
                     <id root="32931291-25d7-4a36-84aa-a1b3e394df13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Potential for Tumor Cell Mobilization</title>
                     <text>
                        <paragraph>When Mozobil is used in combination with G-CSF for HSC
                           mobilization‚ tumor cells may be released from the marrow and
                           subsequently collected in the leukapheresis product. The effect of
                           potential reinfusion of tumor cells has not been
                        well-studied.</paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
               <component>
                  <section ID="f311f15b-c5d5-49d2-a3b0-de05bafc500d">
                     <id root="603c9c80-ea64-4737-9e81-c78c3afa465d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Splenic Enlargement and Potential for Rupture</title>
                     <text>
                        <paragraph>Higher absolute and relative spleen weights associated with
                           extramedullary hematopoiesis were observed following prolonged (2 to 4
                           weeks) daily plerixafor SC administration in rats at doses approximately
                           4-fold higher than the recommended human dose based on body surface area.
                           The effect of Mozobil on spleen size in patients was not specifically
                           evaluated in clinical studies. Evaluate individuals receiving Mozobil in
                           combination with G-CSF who report left upper abdominal pain and/or
                           scapular or shoulder pain for splenic integrity.</paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
               <component>
                  <section ID="a79cecb1-cc43-4f35-ab7d-5f45f78cc7ef">
                     <id root="54e8b0d4-f0e8-4834-bbc0-2da4779bbeaa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis">Pregnancy Category D</content>
                                 </content>
                                 <br/>
                              </content>
                           </content>Mozobil may cause fetal harm when administered to a pregnant
                           woman. Plerixafor was teratogenic in animals. There are no adequate and
                           well-controlled studies in pregnant women using Mozobil. Women of
                           childbearing potential should be advised to avoid becoming pregnant while
                           receiving treatment with Mozobil. If this drug is used during pregnancy,
                           or if the patient becomes pregnant while taking this drug, the patient
                           should be apprised of the potential hazard to the fetus. <content styleCode="italics">
                              <content styleCode="emphasis">[see</content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <linkHtml href="#d7b6e62c-85a0-4317-ba10-602e810bcf7c"> Use In
                                    Specific Populations (8.1)</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">]</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20090810"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="a9a39d89-8ec7-47d6-ae0b-d9ecd13d3762">
               <id root="3f3bac98-8fea-4cc2-836e-866fca8fe049"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20090810"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph> Most common adverse reactions (≥ 10%): diarrhea, nausea,
                           fatigue, injection site reactions, headache, arthralgia, dizziness, and
                           vomiting. (<linkHtml href="#a9a39d89-8ec7-47d6-ae0b-d9ecd13d3762">6</linkHtml>) </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="emphasis">To report SUSPECTED ADVERSE REACTIONS,
                                 contact Genzyme Corporation at 1-877-4MOZOBIL or FDA at
                                 1-800-FDA-1088 or </content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="emphasis">www.fda.gov/medwatch</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="fc3d95e6-52dd-41ac-9bc1-b8ef8b19c887">
                     <id root="f96cdcda-37d1-4bc5-9e4a-c205e577026d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph>The following serious adverse reactions are discussed elsewhere
                           in the labeling: </paragraph>
                        <br/>
                        <list listType="unordered">
                           <item> Potential for tumor cell mobilization in leukemia patients
                                 <content styleCode="italics">
                                 <content styleCode="emphasis"> [see <linkHtml href="#a65b9721-3f7e-4e02-ba13-c6974230e27f">Warnings and
                                       Precautions (5.1)</linkHtml>] </content>
                              </content>
                           </item>
                           <item> Increased circulating leukocytes and decreased platelet counts
                                 <content styleCode="italics">
                                 <content styleCode="emphasis"> [see <linkHtml href="#adcfe034-9bc4-4959-b7b8-b44d0a0f6faf">Warnings and
                                       Precautions (5.2)</linkHtml>] </content>
                              </content>
                           </item>
                           <item> Potential for splenic enlargement <content styleCode="italics">
                                 <content styleCode="emphasis"> [see <linkHtml href="#f311f15b-c5d5-49d2-a3b0-de05bafc500d">Warnings and
                                       Precautions (5.4)</linkHtml>] </content>
                              </content>
                           </item>
                        </list>
                        <paragraph>The most common adverse reactions (≥ 10%) reported in patients
                           who received Mozobil in conjunction with G-CSF regardless of causality
                           and more frequent with Mozobil than placebo during HSC mobilization and
                           apheresis were diarrhea, nausea, fatigue, injection site reactions,
                           headache, arthralgia, dizziness, and vomiting.</paragraph>
                        <paragraph> Safety data for Mozobil in combination with G-CSF were obtained
                           from two randomized placebo-controlled studies (301 patients) and 10
                           uncontrolled studies (242 patients). Patients were primarily treated with
                           Mozobil at daily doses of 0.24 mg/kg SC. Median exposure to Mozobil in
                           these studies was 2 days (range 1 to 7 days).</paragraph>
                        <paragraph> In the two randomized studies in patients with NHL and MM, a
                           total of 301 patients were treated in the Mozobil and G-CSF group and 292
                           patients were treated in the placebo and G-CSF group. Patients received
                           daily morning doses of G-CSF 10 micrograms/kg for 4 days prior to the
                           first dose of Mozobil 0.24 mg/kg SC or placebo and on each morning prior
                           to apheresis. The adverse reactions that occurred in ≥ 5% of the patients
                           who received Mozobil regardless of causality and were more frequent with
                           Mozobil than placebo during HSC mobilization and apheresis are shown in
                              <linkHtml href="#d7c3d40a-4ecd-4bdc-b553-65b06a550165">Table
                           2</linkHtml>.  </paragraph>
                        <paragraph>Because clinical trials are conducted under widely varying
                           conditions, adverse reaction rates observed in the clinical trials of a
                           drug cannot be directly compared to rates in the clinical trials of
                           another drug and may not reflect the rates observed in practice. </paragraph>
                        <br/>
                        <table ID="d7c3d40a-4ecd-4bdc-b553-65b06a550165" width="90%">
                           <caption>Table 2: Adverse Reactions in ≥ 5% of Non-Hodgkin’s Lymphoma and
                              Multiple Myeloma Patients Receiving Mozobil<sup>®</sup> and More Frequent than
                              Placebo During HSC Mobilization and Apheresis</caption>
                           <colgroup>
                              <col align="left"/>
                              <col align="left"/>
                              <col align="left"/>
                              <col align="left"/>
                              <col align="left"/>
                              <col align="left"/>
                              <col align="left"/>
                           </colgroup>
                           <thead styleCode="Lrule Rrule Toprule Botrule">
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" align="center"/>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center" colspan="6"> Percent of Patients (%)</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center"> </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center" colspan="3">  Mozobil<sup>®</sup> and G-CSF<br/>(n = 301) </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center" colspan="3"> Placebo and G-CSF<br/>(n = 292) </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Botrule" align="center"> </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                                       All<br/>Grades<footnote ID="abc8492f-216b-456a-ac2c-1564d70f5f0d">  Grades based on
                                       criteria from the World Health Organization
                                    (WHO)</footnote>   </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                                    Grade<br/>3 </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                                    Grade<br/>4 </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                                    All<br/>Grades </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                                    Grade<br/>3 </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                                    Grade<br/>4 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Gastrointestinal disorders
                                       </content>
                                    </content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">   
                                    Diarrhea</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 37</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">&lt; 1</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">17</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">    Nausea</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">34</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">1</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">22</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">   
                                    Vomiting    </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">10</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">&lt;
                                    1</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">6</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">   
                                    Flatulence</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">7</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">3</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">General disorders and
                                          administration site conditions </content>
                                    </content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">    Injection site reactions        </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">34</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">10</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">   
                                    Fatigue </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">27</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">25</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Musculoskeletal and connective
                                          tissue disorders     </content>
                                    </content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">   
                                    Arthralgia </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">13</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">12</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Nervous system disorders
                                       </content>
                                    </content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">   
                                    Headache</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">22</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">&lt; 1</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">21</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">1</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">   
                                    Dizziness</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">11</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">6</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Psychiatric disorders
                                       </content>
                                    </content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="left">  
                                    Insomnia</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">7</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">5</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In the randomized studies, 34% of patients with NHL or MM had
                           mild to moderate injection site reactions at the site of subcutaneous
                           administration of Mozobil. These included erythema, hematoma, hemorrhage,
                           induration, inflammation, irritation, pain, paresthesia, pruritus, rash,
                           swelling, and urticaria.</paragraph>
                        <paragraph>Mild to moderate systemic reactions were observed in less than 1%
                           of patients approximately 30 min after Mozobil administration. Events
                           included one or more of the following: urticaria (n = 2), periorbital
                           swelling (n = 2), dyspnea (n = 1) or hypoxia (n = 1). Symptoms generally
                           responded to treatments (e.g., antihistamines, corticosteroids, hydration
                           or supplemental oxygen) or resolved spontaneously. </paragraph>
                        <paragraph> Vasovagal reactions, orthostatic hypotension, and/or syncope can
                           occur following subcutaneous injections.<content styleCode="italics">
                              <content styleCode="emphasis"> </content>
                           </content>In Mozobil oncology and healthy volunteer clinical studies,
                           less than 1% of subjects experienced vasovagal reactions following
                           subcutaneous administration of Mozobil doses ≤ 0.24 mg/kg. The majority
                           of these events occurred within 1 hour of Mozobil administration. Because
                           of the potential for these reactions, appropriate precautions should be
                           taken. </paragraph>
                        <paragraph> Other adverse reactions in the randomized studies that occurred
                           in &lt; 5% of patients but were reported as related to Mozobil during
                           HSC mobilization and apheresis included abdominal pain, hyperhidrosis,
                           abdominal distention, dry mouth, erythema, stomach discomfort, malaise,
                           hypoesthesia oral, constipation, dyspepsia, and musculoskeletal
                        pain.</paragraph>
                     </text>
                     <effectiveTime value="20090810"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="e67413f4-8ae4-4528-a6e3-19e7d92795da">
               <id root="1b652ef1-a6e7-454b-bd3b-624c1088011e"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph> Based on <content styleCode="italics">
                        <content styleCode="emphasis">in vitro</content>
                     </content> data, plerixafor is not a substrate, inhibitor or inducer of human
                     cytochrome P450 isozymes. Plerixafor is not likely to be implicated in <content styleCode="italics">
                        <content styleCode="emphasis">in vivo</content>
                     </content> drug-drug interactions involving cytochrome P450s. At concentrations
                     similar to what are seen clinically, plerixafor did not act as a substrate or
                     inhibitor of P-glycoprotein in an <content styleCode="italics">
                        <content styleCode="emphasis">in vitro</content>
                     </content> study. <content styleCode="italics">
                        <content styleCode="emphasis"> [see <linkHtml href="#f20a0ec7-0d1d-4f36-b7de-b7cbb354d273">Clinical Pharmacology
                              (12.3)</linkHtml>] </content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20090807"/>
            </section>
         </component>
         <component>
            <section ID="d1fcb503-ab47-41bd-b9ee-28566a75c189">
               <id root="23308fae-9aab-4bc3-b323-ace1f2f384ee"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20090810"/>
               <component>
                  <section ID="d7b6e62c-85a0-4317-ba10-602e810bcf7c">
                     <id root="542e27be-99f4-419d-851a-60a3e88833a1"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis"> Pregnancy Category D</content>
                                 </content>
                                 <br/>
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis"/>
                                 </content>
                              </content>
                           </content>Plerixafor was teratogenic in animals. Plerixafor administered
                           to pregnant rats induced embryo-fetal toxicities including fetal death,
                           increased resorptions and post-implantation loss, decreased fetal
                           weights, anophthalmia, shortened digits, cardiac interventricular septal
                           defect, ringed aorta, globular heart, hydrocephaly, dilatation of
                           olfactory ventricles, and retarded skeletal development. Embryo-fetal
                           toxicities occurred mainly at a dose of 90 mg/m<sup>2</sup>
                           (approximately 10 times the recommended human dose of 0.24 mg/kg when
                           compared on a mg/m<sup>2</sup> basis or 10 times the AUC in subjects with
                           normal renal function who received a single dose of 0.24 mg/kg).
                        </paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
               <component>
                  <section ID="b9a0fa95-f8ce-45d9-b4b2-8b6610804c37">
                     <id root="d9c199f3-0d62-4631-8968-5d5df19f0905"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether plerixafor is excreted in human milk.
                           Because many drugs are excreted in human milk, and because of the
                           potential for serious adverse reactions in nursing infants from Mozobil,
                           a decision should be made whether to discontinue nursing or to
                           discontinue the drug, taking into account the importance of the drug to
                           the mother.</paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
               <component>
                  <section ID="dc9f64dd-ae60-46f7-90c0-93a276af635b">
                     <id root="25a97237-325c-4271-b3af-85edfcd68797"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of Mozobil in pediatric patients have not
                           been established in controlled clinical studies. </paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
               <component>
                  <section ID="e5f28ccf-439f-4739-bcde-bcc0f9bc9540">
                     <id root="0969dace-1200-435e-a399-4cc242b18a48"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of subjects in controlled clinical studies of
                           Mozobil, 24% were 65 and over, while 0.8% were 75 and over. No overall
                           differences in safety or effectiveness were observed between these
                           subjects and younger subjects, and other reported clinical experience has
                           not identified differences in responses between the elderly and younger
                           patients, but greater sensitivity of some older individuals cannot be
                           ruled out.</paragraph>
                        <paragraph> Since plerixafor is mainly excreted by the kidney, no dose
                           modifications are necessary in elderly individuals with normal renal
                           function.  In general, care should be taken in dose selection for elderly
                           patients due to the greater frequency of decreased renal function with
                           advanced age.  Dosage adjustment in elderly patients with CL<sub>CR</sub>
                           ≤ 50 mL/min is recommended. <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">[see </content>
                                 </content>
                                 <linkHtml href="#b7351d1e-52b7-49ba-bc0d-a6aca4498a91">Dosage and
                                    Administration (2.3)</linkHtml>
                                 <content styleCode="italics">
                                    <content styleCode="emphasis"> and </content>
                                 </content>
                                 <linkHtml href="#f20a0ec7-0d1d-4f36-b7de-b7cbb354d273">Clinical
                                    Pharmacology (12.3)</linkHtml>
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">]</content>
                                 </content>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20090810"/>
                  </section>
               </component>
               <component>
                  <section ID="a193fa99-2de5-48a9-9061-cf285ae326fb">
                     <id root="8d6866f1-1240-4cd6-a3c2-20bafd670e80"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph> In patients with moderate and severe renal impairment
                           (CL<sub>CR</sub> ≤ 50 mL/min), reduce the dose of plerixafor by one-third
                           to 0.16 mg/kg. <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">[see </content>
                                 </content>
                                 <linkHtml href="#b7351d1e-52b7-49ba-bc0d-a6aca4498a91">Dosage and
                                    Administration (2.3)</linkHtml>
                                 <content styleCode="italics">
                                    <content styleCode="emphasis"> and </content>
                                 </content>
                                 <linkHtml href="#f20a0ec7-0d1d-4f36-b7de-b7cbb354d273">Clinical
                                    Pharmacology (12.3)</linkHtml>
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">]</content>
                                 </content>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20090810"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ced582b1-5a76-44a0-91c1-1b452e236a4d">
               <id root="ebe739b9-28c4-4239-af80-783a0b474ff1"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Based on limited data at doses above the recommended dose of 0.24 mg/kg
                     SC, the frequency of gastrointestinal disorders, vasovagal reactions,
                     orthostatic hypotension, and/or syncope may be higher.</paragraph>
               </text>
               <effectiveTime value="20090528"/>
            </section>
         </component>
         <component>
            <section ID="b4c8dabe-86af-4158-b697-527427ba2efd">
               <id root="d6e138e0-16a3-478b-ac01-fd8ba943dd3e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Mozobil (plerixafor injection) is a sterile, preservative-free, clear,
                     colorless to pale yellow, isotonic solution for subcutaneous injection. Each mL
                     of the sterile solution contains 20 mg of plerixafor.  Each single-use vial is
                     filled to deliver 1.2 mL of the sterile solution that contains 24 mg of
                     plerixafor and 5.9 mg of sodium chloride in Water for Injection adjusted to a
                     pH of 6.0 to 7.5 with hydrochloric acid and with sodium hydroxide, if
                     required.  </paragraph>
                  <paragraph> Plerixafor is a hematopoietic stem cell mobilizer with a chemical name
                     1, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane. 
                     It has the molecular formula C<sub>28</sub>H<sub>54</sub>N<sub>8.  </sub>The
                     molecular weight of plerixafor is 502.79 g/mol. The structural formula is
                     provided in <linkHtml href="#b4c8dabe-86af-4158-b697-527427ba2efd">Figure
                     1</linkHtml>. </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">Figure 1: Structural Formula </content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM190"/>
                  </paragraph>
                  <paragraph>Plerixafor is a white to off-white crystalline solid.  It is
                     hygroscopic. Plerixafor has a typical melting point of 131.5 °C. The partition
                     coefficient of plerixafor between 1-octanol and pH 7 aqueous buffer is &lt;
                     0.1.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20090729"/>
               <component>
                  <observationMedia ID="MM190">
                     <text>Figure 1: Structural Formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mozobil-figure-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="e044f255-33ec-4f9d-ad8c-da1cd37fbf18">
               <id root="fcd2f81c-f6fd-4e7e-b329-ff7dbe6120da"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20090810"/>
               <component>
                  <section ID="c1c0dff1-c46f-485c-b70d-7a5fa2960450">
                     <id root="368cdc0a-9cd6-4068-873a-c37d02d10f3b"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph> Plerixafor is an inhibitor of the CXCR4 chemokine receptor and
                           blocks binding of its cognate ligand, stromal cell-derived factor-1α
                           (SDF-1α).  SDF-1α and CXCR4 are recognized to play a role in the
                           trafficking and homing of human hematopoietic stem cells (HSCs) to the
                           marrow compartment. Once in the marrow, stem cell CXCR4 can act to help
                           anchor these cells to the marrow matrix, either directly via SDF-1α or
                           through the induction of other adhesion molecules. Treatment with
                           plerixafor resulted in leukocytosis and elevations in circulating
                           hematopoietic progenitor cells in mice, dogs and humans.  CD34+ cells
                           mobilized by plerixafor were capable of engraftment with long-term
                           repopulating capacity up to one year in canine transplantation models.
                        </paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
               <component>
                  <section ID="e78b8088-6b99-4f4f-8812-0147d58ffdc1">
                     <id root="74fa9563-908e-4957-9218-fae1b7f604a1"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph> Data on the fold increase in peripheral blood CD34+ cell count
                           (cells/mcL) by apheresis day were evaluated in two placebo-controlled
                           clinical studies in patients with NHL and MM (Study 1 and Study 2,
                           respectively). The fold increase in CD34+ cell count (cells/mcL) over the
                           24-hour period starting from the day prior to the first apheresis and
                           ending the next morning just before the first apheresis is summarized in
                              <linkHtml href="#b6313b9f-56c2-4a4c-acf5-f21e5ad910d6">Table
                           3</linkHtml>.  During this 24-hour period, a single dose of Mozobil or
                           placebo was administered 10 to 11 hours prior to apheresis. </paragraph>
                        <table ID="b6313b9f-56c2-4a4c-acf5-f21e5ad910d6" width="70%">
                           <caption>Table 3: Fold Increase in Peripheral Blood CD34+ Cell Count
                              Following Pretreatment with G-CSF and Administration of Plerixafor</caption>
                           <colgroup>
                              <col width="30%" align="left"/>
                              <col width="15%" align="left"/>
                              <col width="20%" align="left"/>
                              <col width="15%" align="left"/>
                              <col width="30%" align="left"/>
                           </colgroup>
                           <thead styleCode="Lrule Rrule Toprule Botrule">
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule" align="center">  <br/> Study </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center" colspan="2">Mozobil<sup>®</sup> and G-CSF</th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center" colspan="2">Placebo and G-CSF</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule Botrule" align="center"> </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center"> Median</th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center"> Mean
                                    (SD)</th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center">  Median  </th>
                                 <th styleCode="Lrule Rrule Toprule Botrule" align="center"> Mean
                                    (SD)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> Study 1</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 5.0</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 6.1
                                    (5.4)</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 1.4</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 1.9
                                    (1.5)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> Study 2</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 4.8</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 6.4
                                    (6.8)</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 1.7</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 2.4
                                    (7.3)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In pharmacodynamic studies of Mozobil in healthy volunteers, peak
                           mobilization of CD34+ cells was observed between 6 and 9 hours after
                           administration. In pharmacodynamic studies of Mozobil in conjunction with
                           G-CSF in healthy volunteers, a sustained elevation in the peripheral
                           blood CD34+ count was observed from 4 to 18 hours after plerixafor
                           administration with a peak CD34+ count between 10 and 14
                        hours.</paragraph>
                     </text>
                     <effectiveTime value="20090807"/>
                  </section>
               </component>
               <component>
                  <section ID="f20a0ec7-0d1d-4f36-b7de-b7cbb354d273">
                     <id root="fb5b78b5-c3fc-4d76-a53d-8cae380f41b0"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The single-dose pharmacokinetics of plerixafor 0.24 mg/kg were
                           evaluated in patients with NHL and MM following pre-treatment with G-CSF
                           (10 micrograms/kg once daily for 4 consecutive days).  Plerixafor
                           exhibits linear kinetics between the 0.04 mg/kg to 0.24 mg/kg dose
                           range.  The pharmacokinetics of plerixafor were similar across clinical
                           studies in healthy subjects who received plerixafor alone and NHL and MM
                           patients who received plerixafor in combination with G-CSF.</paragraph>
                        <paragraph> A population pharmacokinetic analysis incorporated plerixafor
                           data from 63 subjects (NHL patients, MM patients, subjects with varying
                           degrees of renal impairment, and healthy subjects) who received a single
                           SC dose (0.04 mg/kg to 0.24 mg/kg) of plerixafor.  A two-compartment
                           disposition model with first order absorption and elimination was found
                           to adequately describe the plerixafor concentration-time profile.
                           Significant relationships between clearance and creatinine clearance
                              (CL<sub>CR</sub>), as well as between central volume of distribution
                           and body weight were observed.  The distribution half-life
                           (t<sub>1/2α</sub>) was estimated to be 0.3 hours and the terminal
                           population half-life (t<sub>1/2β</sub>) was 5.3 hours in patients with
                           normal renal function. </paragraph>
                        <paragraph> The population pharmacokinetic analysis showed that the
                           mg/kg-based dosage results in an increased plerixafor exposure
                              (AUC<sub>0-24h</sub>) with increasing body weight.  There is limited
                           experience with the 0.24 mg/kg dose of plerixafor in patients weighing
                           above 160 kg.  Therefore the dose should not exceed that of a 160 kg
                           patient (i.e., 40 mg/day if CL<sub>CR</sub> is &gt; 50 mL/min and 27
                           mg/day if CL<sub>CR</sub> is ≤ 50 mL/min).  <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">[see </content>
                                 </content>
                                 <linkHtml href="#c7052a30-f0a9-407a-87f7-5c4942f151cb">Dosage and
                                    Administration (2.1</linkHtml>
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">, </content>
                                 </content>
                                 <linkHtml href="#b7351d1e-52b7-49ba-bc0d-a6aca4498a91">2.3)</linkHtml>
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">]</content>
                                 </content>
                              </content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis">Absorption</content>
                                 </content>
                                 <br/>
                              </content>
                           </content>Peak plasma concentrations occurred at approximately 30 - 60
                           minutes after a SC dose. </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis">Distribution</content>
                                 </content>
                                 <br/>
                              </content>
                           </content>Plerixafor is bound to human plasma proteins up to 58%. The
                           apparent volume of distribution of plerixafor in humans is 0.3 L/kg
                           demonstrating that plerixafor is largely confined to, but not limited to,
                           the extravascular fluid space. </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis">Metabolism</content>
                                 </content>
                                 <br/>
                              </content>
                           </content>The metabolism of plerixafor was evaluated with <content styleCode="italics">
                              <content styleCode="emphasis">in vitro</content>
                           </content> assays.  Plerixafor is not metabolized as shown in assays
                           using human liver microsomes or human primary hepatocytes and does not
                           exhibit inhibitory activity <content styleCode="italics">
                              <content styleCode="emphasis">in vitro</content>
                           </content> towards the major drug metabolizing cytochrome P450 enzymes
                           (1A2, 2C9, 2C19, 2D6, and 3A4/5). In<content styleCode="italics">
                              <content styleCode="emphasis"> in vitro</content>
                           </content> studies with human hepatocytes, plerixafor does not induce
                           CYP1A2, CYP2B6, or CYP3A4 enzymes. These findings suggest that plerixafor
                           has a low potential for involvement in cytochrome P450-dependent
                           drug-drug interactions. </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis">Elimination</content>
                                 </content>
                                 <br/>
                              </content>
                           </content>The major route of elimination of plerixafor is urinary.
                           Following a 0.24 mg/kg dose in healthy volunteers with normal renal
                           function, approximately 70% of the dose was excreted in the urine as the
                           parent drug during the first 24 hours following administration. In
                           studies with healthy subjects and patients, the terminal half-life in
                           plasma ranges between 3 and 5 hours. At concentrations similar to what
                           are seen clinically, plerixafor did not act as a substrate or inhibitor
                           of P-glycoprotein in an <content styleCode="italics">
                              <content styleCode="emphasis">in vitro</content>
                           </content> study with MDCKII and MDCKII-MDR1 cell
                           models. </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis">Renal Impairment</content>
                                 </content>
                                 <br/>
                              </content>
                           </content>Following a single 0.24 mg/kg SC dose, plerixafor clearance was
                           reduced in subjects with varying degrees of renal impairment and was
                           positively correlated with CL<sub>CR</sub>.  The mean AUC<sub>0-24h
                           </sub>of plerixafor in subjects with mild (CL<sub>CR</sub> 51-80 mL/min),
                           moderate (CL<sub>CR</sub> 31-50 mL/min), and severe (CL<sub>CR</sub>
                           &lt; 31 mL/min) renal impairment was 7%, 32%, and 39% higher than
                           healthy subjects with normal renal function, respectively.  Renal
                           impairment had no effect on C<sub>max</sub>. A population pharmacokinetic
                           analysis indicated an increased exposure
                           (AUC<sub>0-24h</sub>)<sub> </sub>in patients with moderate and severe
                           renal impairment compared to patients with CL<sub>CR</sub> &gt; 50
                           mL/min. These results support a dose reduction of one-third in patients
                           with moderate to severe renal impairment (CL<sub>CR</sub> ≤ 50 mL/min) in
                           order to match the exposure in patients with normal renal function. The
                           population pharmacokinetic analysis showed that the mg/kg-based dosage
                           results in an increased plerixafor exposure (AUC<sub>0-24h</sub>) with
                           increasing body weight; therefore if CL<sub>CR</sub> is ≤ 50 mL/min the
                           dose should not exceed 27 mg/day.  <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">[see </content>
                                 </content>
                                 <linkHtml href="#b7351d1e-52b7-49ba-bc0d-a6aca4498a91">Dosage and
                                    Administration (2.3)</linkHtml>
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">]</content>
                                 </content>
                              </content>
                           </content>
                        </paragraph>
                        <paragraph>Since plerixafor is primarily eliminated by the kidneys,
                           coadministration of plerixafor with drugs that reduce renal function or
                           compete for active tubular secretion may increase serum concentrations of
                           plerixafor or the coadministered drug.  The effects of coadministration
                           of plerixafor with other drugs that are renally eliminated or are known
                           to affect renal function have not been evaluated. </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis">Race</content>
                                 </content>
                                 <br/>
                              </content>
                           </content>Clinical data show similar plerixafor pharmacokinetics for
                           Caucasians and African-Americans, and the effect of other racial/ethnic
                           groups has not been studied.  </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis">Gender</content>
                                 </content>
                                 <br/>
                              </content>
                           </content>Clinical data show no effect of gender on plerixafor
                           pharmacokinetics. </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">
                              <content styleCode="emphasis">
                                 <content styleCode="bold italics">
                                    <content styleCode="emphasis">Age</content>
                                 </content>
                                 <br/>
                              </content>
                           </content>Clinical data show no effect of age on plerixafor
                           pharmacokinetics. </paragraph>
                     </text>
                     <effectiveTime value="20090810"/>
                  </section>
               </component>
               <component>
                  <section ID="b8dae177-a590-4367-a3a9-6c90d2454413">
                     <id root="4ec88128-32f1-4b1f-b663-98a993c60954"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.4 QT/QTc Prolongation</title>
                     <text>
                        <paragraph>There is no indication of a QT/QTc prolonging effect of Mozobil
                           in single doses up to 0.40 mg/kg. In a randomized, double-blind,
                           crossover study, 48 healthy subjects were administered a single
                           subcutaneous dose of Mozobil (0.24 mg/kg and 0.40 mg/kg) and placebo.
                           Peak concentrations for 0.40 mg/kg Mozobil were approximately 1.8-fold
                           higher than the peak concentrations following the 0.24 mg/kg single
                           subcutaneous dose.</paragraph>
                     </text>
                     <effectiveTime value="20100420"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="b71cc5b2-2bba-476b-a837-ad11f96add2f">
               <id root="6fda0123-bacd-4b6a-bb66-bb32a30ba5a0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20090528"/>
               <component>
                  <section ID="fb2e33af-3c73-4933-a0e4-87ee2f58735b">
                     <id root="34b2c327-65a3-47a5-aa41-310d50e12b8e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity studies with plerixafor have not been conducted.</paragraph>
                        <paragraph> Plerixafor was not genotoxic in an <content styleCode="italics">
                              <content styleCode="emphasis">in vitro</content>
                           </content> bacterial mutation assay (Ames test in <content styleCode="italics">
                              <content styleCode="emphasis">Salmonella</content>
                           </content>), an <content styleCode="italics">
                              <content styleCode="emphasis">in vitro</content>
                           </content> chromosomal aberration test using V79 Chinese hamster cells,
                           or an <content styleCode="italics">
                              <content styleCode="emphasis">in vivo</content>
                           </content> bone marrow micronucleus test in rats after subcutaneous doses
                           up to 25 mg/kg (150 mg/m<sup>2</sup>). </paragraph>
                        <paragraph>The effect of plerixafor on human fertility is unknown.  The
                           effect of plerixafor on male or female fertility was not studied in
                           designated reproductive toxicology studies.  The staging of
                           spermatogenesis measured in a 28-day repeated dose toxicity study in rats
                           revealed no abnormalities considered to be related to plerixafor.  No
                           histopathological evidence of toxicity to male or female reproductive
                           organs was observed in 28-day repeated dose toxicity studies.</paragraph>
                     </text>
                     <effectiveTime value="20090528"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="e783297a-d785-4ab5-85a1-1f3abcb5fce5">
               <id root="271f0877-6b18-4ede-9bb2-e3409c5b5e04"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy and safety of Mozobil in conjunction with G-CSF in
                     non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) were evaluated in two
                     placebo-controlled studies (Studies 1 and 2).  Patients were randomized to
                     receive either Mozobil 0.24 mg/kg or placebo on each evening prior to
                     apheresis. Patients received daily morning doses of G-CSF 10 micrograms/kg for
                     4 days prior to the first dose of Mozobil or placebo and on each morning prior
                     to apheresis. Two hundred and ninety-eight (298) NHL patients were included
                     in the primary efficacy analyses for Study 1. The mean age was 55.1 years
                     (range 29-75) and 57.5 years (range 22-75) in the Mozobil and placebo groups,
                     respectively, and 93% of subjects were Caucasian. Three hundred and two (302)
                     MM patients were included in the primary efficacy analyses for Study 2. The
                     mean age was 58.2 years (range 28-75) and 58.5 years (range 28-75) in the
                     Mozobil and placebo groups, respectively, and 81% of subjects were Caucasian.</paragraph>
                  <paragraph> In Study 1, 59% of NHL patients who were mobilized with Mozobil and
                     G-CSF collected ≥ 5 X 10<sup>6</sup> CD34+ cells/kg from the peripheral blood
                     in four or fewer apheresis sessions, compared with 20% of patients who were
                     mobilized with placebo and G-CSF (p &lt; 0.001). Other CD34+ cell
                     mobilization outcomes showed similar findings (<linkHtml href="#dd20df67-4df2-44ef-87f7-54075985360d">Table 4</linkHtml>).  </paragraph>
                  <br/>
                  <table ID="dd20df67-4df2-44ef-87f7-54075985360d">
                     <caption>Table 4: Study 1 Efficacy Results - CD34+ Cell Mobilization in NHL
                        Patients</caption>
                     <colgroup>
                        <col align="left"/>
                        <col align="left"/>
                        <col align="left"/>
                        <col align="left"/>
                     </colgroup>
                     <thead styleCode="Lrule Rrule Toprule Botrule">
                        <tr>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center"> Efficacy
                              Endpoint</th>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center"> Mozobil<sup>®</sup>
                              and<br/>G-CSF<br/>(n = 150) </th>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center"> Placebo
                              and<br/>G-CSF<br/>(n = 148) </th>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                                 p-value<footnote ID="ac31767c-e064-4ecd-8fea-cebaca99eabb">  p-value calculated using Pearson's Chi-Squared test</footnote>  
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="left"> Patients
                              achieving ≥ 5 X 10<sup>6</sup> cells/kg in ≤ 4 apheresis days </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">89 (59%)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">29 (20%)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">&lt; 0.001</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="left"> Patients
                              achieving ≥ 2 X 10<sup>6</sup> cells/kg in ≤ 4 apheresis days </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">130 (87%)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">70 (47%)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">&lt; 0.001</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> The median number of days to reach ≥ 5 x 10<sup>6</sup> CD34+ cells/kg
                     was 3 days for the Mozobil group and not evaluable for the placebo
                        group. <linkHtml href="#bc54171f-5c7f-4a7b-af5c-d2ba877f4399">Table
                     5</linkHtml> presents the proportion of patients who achieved ≥ 5 x
                     10<sup>6</sup> CD34+ cells/kg by apheresis day. </paragraph>
                  <br/>
                  <table ID="bc54171f-5c7f-4a7b-af5c-d2ba877f4399">
                     <caption> Table 5: Study 1 Efficacy Results - Proportion of Patients Who
                        Achieved ≥ 5 x 10<sup>6</sup> CD34+ cells/kg by Apheresis Day in NHL
                        Patients </caption>
                     <colgroup>
                        <col align="left"/>
                        <col align="left"/>
                        <col align="left"/>
                     </colgroup>
                     <thead styleCode="Lrule Rrule Toprule Botrule">
                        <tr>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                              <content styleCode="bold">
                                 <content styleCode="emphasis">Days </content>
                              </content>
                           </th>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                              <content styleCode="bold">
                                 <content styleCode="emphasis"> Proportion<footnote ID="c9bd9d64-63a8-4019-a60c-8eac5f5cbfd1">
                                       <content styleCode="bold">
                                          <content styleCode="emphasis"/>
                                       </content>  Percents determined by Kaplan Meier method
                                 </footnote>  <br/>in Mozobil<sup>®</sup> and G-CSF<br/>(n=147<footnote ID="d9016517-46e8-431a-91b5-a4be10e98163">
                                       <content styleCode="bold">
                                          <content styleCode="emphasis"/>
                                       </content>  n includes all patients who received at least one
                                       day of apheresis </footnote>) </content>
                              </content>
                           </th>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                              <content styleCode="bold">
                                 <content styleCode="emphasis">  Proportion<footnoteRef IDREF="c9bd9d64-63a8-4019-a60c-8eac5f5cbfd1"/>  <br/>in
                                    Placebo and G-CSF<br/>(n = 142<footnoteRef IDREF="d9016517-46e8-431a-91b5-a4be10e98163"/>) </content>
                              </content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">1</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">27.9%</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">4.2%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">2</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">49.1%</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">14.2%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">3</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">57.7%</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">21.6%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">4</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">65.6%</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">24.2%</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> In Study 2, 72% of MM patients who were mobilized with Mozobil and
                     G-CSF collected ≥ 6 X 10<sup>6</sup> CD34+ cells/kg from the peripheral blood
                     in two or fewer apheresis sessions, compared with 34% of patients who were
                     mobilized with placebo and G-CSF (p &lt; 0.001). Other CD34+ cell
                     mobilization outcomes showed similar findings (<linkHtml href="#c7af56fd-43f9-499b-9dc3-ca5308884f33">Table 6</linkHtml>).  </paragraph>
                  <table ID="c7af56fd-43f9-499b-9dc3-ca5308884f33">
                     <caption>Table 6: Study 2 Efficacy Results - CD34+ Cell Mobilization in
                        Multiple Myeloma Patients</caption>
                     <colgroup>
                        <col align="left"/>
                        <col align="left"/>
                        <col align="left"/>
                        <col align="center"/>
                     </colgroup>
                     <thead styleCode="Lrule Rrule Toprule Botrule">
                        <tr>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center"> Efficacy
                              Endpoint   </th>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center">  Mozobil<sup>®</sup>
                              and<br/>G-CSF<br/>(n=148) </th>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center"> Placebo
                              and<br/>G-CSF<br/>(n=154) </th>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center"> 
                                 p-value<footnote ID="fe7a8620-f0cb-4a13-89f1-c7576ff78dc3">  p-value calculated using Pearson's Chi-Squared test</footnote> 
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="left"> Patients
                              achieving ≥ 6 X 10<sup>6</sup> cells/kg in ≤ 2 apheresis days </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 106 (72%)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 53 (34%)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> &lt;
                              0.001</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="left"> Patients
                              achieving ≥ 6 X 10<sup>6</sup> cells/kg in ≤ 4 apheresis days   </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">112 (76%)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">79 (51%)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> &lt;
                              0.001</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="left"> Patients
                              achieving ≥ 2 X 10<sup>6</sup> cells/kg in ≤ 4 apheresis days    </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center">141 (95%)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 136 (88%)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 0.028</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> The median number of days to reach ≥ 6 x 10<sup>6</sup> CD34+ cells/kg
                     was 1 day for the Mozobil group and 4 days for the placebo group. <linkHtml href="#ebd8802d-e942-4a96-8de9-962a9bdee860">Table 7</linkHtml> presents the
                     proportion of patients who achieved ≥ 6 x 10<sup>6</sup> CD34+ cells/kg by
                     apheresis day. </paragraph>
                  <table ID="ebd8802d-e942-4a96-8de9-962a9bdee860">
                     <caption> Table 7: Study 2 – Proportion of Patients Who Achieved ≥ 6 x
                        10<sup>6</sup> CD34+ cells/kg by Apheresis Day in MM Patients </caption>
                     <colgroup>
                        <col align="left"/>
                        <col align="left"/>
                        <col align="left"/>
                     </colgroup>
                     <thead styleCode="Lrule Rrule Toprule Botrule">
                        <tr>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center">Days </th>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                                 Proportion<footnote ID="c965025e-861a-46d8-a2e7-a274c3f57987">  Percents determined by Kaplan Meier method</footnote>  <br/>in
                              Mozobil<sup>®</sup> and G-CSF<br/>(n=144<footnote ID="d0459edd-2085-4d69-8e9e-9df3760075e3">  n includes all patients
                                 who received at least one day of apheresis</footnote>)  </th>
                           <th styleCode="Lrule Rrule Toprule Botrule" align="center">
                                  Proportion<footnoteRef IDREF="c965025e-861a-46d8-a2e7-a274c3f57987"/>  <br/>in Placebo and
                                 G-CSF<br/>(n=150<footnoteRef IDREF="d0459edd-2085-4d69-8e9e-9df3760075e3"/>)</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 1</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 54.2%</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 17.3%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 2</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 77.9%</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 35.3%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 3</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 86.8%</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 48.9%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 4</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 86.8%</td>
                           <td styleCode="Lrule Rrule Toprule Botrule" align="center"> 55.9%</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Multiple factors can influence time to engraftment and graft durability
                     following stem cell transplantation. For transplanted patients in the Phase 3
                     studies, time to neutrophil and platelet engraftment and graft durability were
                     similar across the treatment groups. </paragraph>
                  <br/>
               </text>
               <effectiveTime value="20090810"/>
            </section>
         </component>
         <component>
            <section ID="eae2f4bd-0427-4c3c-90e7-734eed63593a">
               <id root="74c406eb-7ffe-4714-9986-b037d154a295"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Each single-use vial is filled to deliver 1.2 mL of 20 mg/mL solution
                     containing 24 mg of plerixafor.</paragraph>
                  <paragraph>NDC Number: 58468-0140-1</paragraph>
                  <br/>
                  <list listType="unordered">
                     <item> Store at 25<sup>o</sup>C (77<sup>o</sup>F); excursions permitted to
                           15<sup>o</sup>-30<sup>o</sup>C (59<sup>o</sup>-86<sup>o</sup>F). [see USP
                        Controlled Room temperature] </item>
                     <item>Each vial of Mozobil is intended for single use only. Any unused drug
                        remaining after injection must be discarded.</item>
                  </list>
               </text>
               <effectiveTime value="20090528"/>
            </section>
         </component>
         <component>
            <section ID="c0d1e68d-73cc-483d-92b6-9994162d4b37">
               <id root="978f9928-e395-4ba3-b93a-96b894b6f855"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph> Advise patients of the signs and symptoms of potential systemic
                     reactions such as urticaria, periorbital swelling, dyspnea, or hypoxia during
                     and following Mozobil injection. <content styleCode="italics">
                        <content styleCode="emphasis">
                           <content styleCode="italics">
                              <content styleCode="emphasis">[see </content>
                           </content>
                           <linkHtml href="#fc3d95e6-52dd-41ac-9bc1-b8ef8b19c887">Adverse Reactions
                              (6.1)</linkHtml>
                        </content>
                     </content>
                     <content styleCode="italics">
                        <content styleCode="emphasis">] </content>
                     </content>
                  </paragraph>
                  <paragraph> Patients should inform a health care professional immediately if
                     symptoms of vasovagal reactions such as orthostatic hypotension or syncope
                     occur during or shortly after their Mozobil injection. <content styleCode="italics">
                        <content styleCode="emphasis">
                           <content styleCode="italics">
                              <content styleCode="emphasis">[see </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <linkHtml href="#fc3d95e6-52dd-41ac-9bc1-b8ef8b19c887">Adverse
                                    Reactions (6.1)</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">]</content>
                           </content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph> If patients experience itching, rash, or reaction at the site of
                     injection, they should notify a health care professional as these symptoms have
                     been treated with over-the-counter medications during clinical trials. <content styleCode="italics">
                        <content styleCode="emphasis">
                           <content styleCode="italics">
                              <content styleCode="emphasis">[see </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <linkHtml href="#fc3d95e6-52dd-41ac-9bc1-b8ef8b19c887">Adverse
                                    Reactions (6.1)</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">]</content>
                           </content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph> Inform patients that Mozobil may cause gastrointestinal disorders,
                     including diarrhea, nausea, vomiting, flatulence, and abdominal pain. Patients
                     should be told how to manage specific gastrointestinal disorders and to inform
                     their health care professional if severe events occur following Mozobil
                     injection. <content styleCode="italics">
                        <content styleCode="emphasis">
                           <content styleCode="italics">
                              <content styleCode="emphasis">[see </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">
                                 <linkHtml href="#fc3d95e6-52dd-41ac-9bc1-b8ef8b19c887">Adverse
                                    Reactions (6.1)</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="emphasis">]</content>
                           </content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph> Advise female patients with reproductive potential to use effective
                     contraceptive methods during Mozobil use. <content styleCode="italics">
                        <content styleCode="emphasis">[see </content>
                     </content>
                     <content styleCode="italics">
                        <content styleCode="emphasis">
                           <linkHtml href="#a79cecb1-cc43-4f35-ab7d-5f45f78cc7ef">Warnings and
                              Precautions (5.5)</linkHtml>
                        </content>
                     </content>
                     <content styleCode="italics">
                        <content styleCode="emphasis"> and </content>
                     </content>
                     <content styleCode="italics">
                        <content styleCode="emphasis">
                           <linkHtml href="#d7b6e62c-85a0-4317-ba10-602e810bcf7c">Use In Specific
                              Populations (8.1)</linkHtml>
                        </content>
                     </content>
                     <content styleCode="italics">
                        <content styleCode="emphasis">]</content>
                     </content>
                  </paragraph>
                  <br/>
                  <br/>
                  <paragraph>Manufactured by: Patheon UK Ltd., Swindon, UK</paragraph>
                  <paragraph>Manufactured for: Genzyme Corporation, 500 Kendall Street, Cambridge,
                     MA 02142 USA</paragraph>
                  <br/>
                  <paragraph>©2010 Genzyme Corporation. All rights reserved.</paragraph>
                  <paragraph>Mozobil is a registered trademark of Genzyme Corporation.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20090810"/>
            </section>
         </component>
         <component>
            <section ID="d0d2e68e-73cc-483d-92b6-9994162d4b37">
               <id root="978f9928-ef95-4ca3-a93a-96b894b6f855"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">Package Label Principal Display Panel - 2mL
                           Carton</content>
                     </content>
                  </paragraph>
                  <paragraph>Carton contains one vial of </paragraph>
                  <paragraph> Mozobil<sup>®</sup>
                     <br/>(plerixafor injection) </paragraph>
                  <paragraph> 24 mg/1.2 mL<br/>(20 mg/mL) </paragraph>
                  <paragraph>For single use only</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>See package insert for dosage and administration</paragraph>
                  <br/>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM260"/>
                  </paragraph>
               </text>
               <effectiveTime value="20090810"/>
               <component>
                  <observationMedia ID="MM260">
                     <text>Package Label - Principal Display Panel - 2mL Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mozobil-figure-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>